种系MAX突变相关的多发性内分泌肿瘤:多发性内分泌腺瘤病5型?
报告两个携带种系MAX突变的家族,患者出现嗜铬细胞瘤、副神经节瘤、垂体神经内分泌肿瘤及其他内分泌与非内分泌肿瘤。家族A中c.200C>A(p.Ala67Asp)变异与嗜铬细胞瘤、神经节神经瘤、神经母细胞瘤及肢端肥大症相关;家族B中截短变异c.22G>T(p.Glu8*)与双侧转移性嗜铬细胞瘤、泌乳素瘤、多腺体甲状旁腺腺瘤、软骨肉瘤及多灶性肺腺癌相关。提示MAX可能是新的多发性内分泌腺瘤病基因。
要点
- 种系MAX突变携带者应筛查嗜铬细胞瘤/副神经节瘤及垂体神经内分泌肿瘤。
- MAX相关肿瘤可包括神经节神经瘤、神经母细胞瘤、甲状旁腺腺瘤、软骨肉瘤和肺腺癌。
- MAX突变肿瘤组织显示MAX染色缺失,支持其致病性。
核心结论
- 种系MAX突变与嗜铬细胞瘤、神经节神经瘤、神经母细胞瘤、垂体神经内分泌肿瘤以及可能的甲状旁腺腺瘤、软骨肉瘤和肺腺癌相关,提示MAX是新的多发性内分泌腺瘤病基因。
研究设计与样本
- 在澳大利亚大学医院对两个携带种系MAX突变的家族进行临床、遗传、免疫组化和功能研究。
- 家族A中多个个体患嗜铬细胞瘤(包括双侧和转移性疾病),两名儿童分别患椎旁神经节神经瘤和腹部神经母细胞瘤;一名个体患肢端肥大症,另一名有垂体增大和IGF-1升高。
- 家族B先证者患双侧转移性嗜铬细胞瘤、泌乳素瘤、多腺体甲状旁腺腺瘤、软骨肉瘤和多灶性肺腺癌。
主要发现
- 家族A中发现种系MAX变异c.200C>A(p.Ala67Asp),所有嗜铬细胞瘤患者和两名儿童均携带,嗜铬细胞瘤组织中存在杂合性缺失。
- 免疫组化显示嗜铬细胞瘤和其他神经嵴肿瘤中MAX染色缺失,体外研究证实该变异为功能丧失。
- 家族B中发现截短种系MAX变异c.22G>T(p.Glu8*)。
临床怎么用
- 对种系MAX突变携带者应进行嗜铬细胞瘤/副神经节瘤和垂体神经内分泌肿瘤的临床筛查。
- MAX相关肿瘤谱可能扩展至神经节神经瘤、神经母细胞瘤、甲状旁腺腺瘤、软骨肉瘤和肺腺癌,需相应监测。
局限性
- 仅基于两个家族的观察性研究,样本量小,关联性需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pathogenic germline MAX variants are associated with pheochromocytoma and paraganglioma (PPGL), pituitary neuroendocrine tumors and, possibly, other endocrine and nonendocrine tumors. OBJECTIVE: To report 2 families with germline MAX variants, pheochromocytomas (PCs) and multiple other tumors. METHODS: Clinical, genetic, immunohistochemical, and functional studies at University hospitals in Australia on 2 families with germline MAX variants undergoing usual clinical care. The main outcome measures were phenotyping; germline and tumor sequencing; immunohistochemistry of PC and other tumors; functional studies of MAX variants. RESULTS: Family A has multiple individuals with PC (including bilateral and metastatic disease) and 2 children (to date, without PC) with neuroendocrine tumors (paravertebral ganglioneuroma and abdominal neuroblastoma, respectively). One individual has acromegaly; immunohistochemistry of PC tissue showed positive growth hormone-releasing hormone staining. Another individual with previously resected PCs has pituitary enlargement and elevated insulin-like growth factor (IGF-1). A germline MAX variant (c.200C>A, p.Ala67Asp) was identified in all individuals with PC and both children, with loss of heterozygosity in PC tissue. Immunohistochemistry showed loss of MAX staining in PCs and other neural crest tumors. In vitro studies confirmed the variant as loss of function. In Family B, the proband has bilateral and metastatic PC, prolactin-producing pituitary tumor, multigland parathyroid adenomas, chondrosarcoma, and multifocal pulmonary adenocarcinomas. A truncating germline MAX variant (c.22G>T, p.Glu8*) was identified. CONCLUSION: Germline MAX mutations are associated with PCs, ganglioneuromas, neuroblastomas, pituitary neuroendocrine tumors, and, possibly, parathyroid adenomas, as well as nonendocrine tumors of chondrosarcoma and lung adenocarcinoma, suggesting MAX is a novel multiple endocrine neoplasia gene.
引用
- Seabrook AJ, Harris JE, Velosa SB, et al. Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? J Clin Endocrinol Metab. 2021. PMID: 33367756. doi:10.1210/clinem/dgaa957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。